Compound ID	CDAMM01175
Common name	Naucleamide C
IUPAC name	19-ethylidene-16-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-2(10),4,6,8,15-pentaen-14-one
Molecular formula	C₂₀H₂₀N₂O₃

Experimental data

Retention time	16.79
Adduct	[M+H]+
Actual mz	337.15
Theoretical mz	337.154
Error	12.09
Ionizaton mode	Positive
Instrument type	LC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score	6.8548

Identifiers and class information

Inchi key	OLFCHDJEYWIHFJ-VYPJIOPDNA-N
Smiles	O=C1C2=C(O)OCC(=CC)C2CC3C=4NC=5C=CC=CC5C4CCN13
Superclass	Organoheterocyclic compounds
Class	Indoles and derivatives

Plant source

Cinnamomum verum J. Presl

External sources

HMDB ID
KNApSAcK ID	C00032057
FooDB ID
DrugBank ID
ChEBI ID
Pubchem Compound ID	73075369
PlantCyc ID
UNPD ID	UNPD110239
Coconut ID	CNP0344004
LipidMAPS ID
NANPDB ID

Pharmacokinetic properties

Number of descriptor values(#stars)	0
Number of non-conjugated amine groups (#amine)	0
Number of amidine and guanidine groups (#amidine)	0
Number of carboxylic acid groups (#acid)	0
Number of non-conjugated amide groups (#amide)	1
Number of rotatable bonds (#rotor)	0
Number of reactive functional groups (#rtvFG)	1
Predicted central nervous system activity (CNS)	0
Molecular weight (mol_MW)	336.39
Computed dipole moment(dipole)	11.171
Total solvent accessible surface area (SASA)	557.017
Hydrophobic component of SASA (FOSA)	267.87
Hydrophilic component of SASA (FISA)	101.778
Pie component of the SASA (PISA)	187.369
Weakly polar component of the SASA (WPSA)	0
Total solvent accesible volume (volume)	1023.74
Number of hydrogen bond donors (donorHB)	1
Number of hydrogen bond acceptors (accptHB)	6
Free energy of solvation of dipole (dip^2/V)	0.121903
Index of cohesive interaction in solids (ACxDN^.5/SA)	0.0107717
Globularity descriptor (glob)	0.881909
Predicted polarizability in cubic angstroms (QPpolrz)	36.606
Predicted hexadecane/gas partition coefficient (QPlogPC16)	10.107
Predicted octanol/gas partition coefficient (QPlogPoct)	18.421
Predicted water/gas partition coefficient (QPlogPw)	12.156
Predicted octanol/water partition coefficient (QPlogPo/w)	2.119
Predicted aqueous solubility (QPlogS)	-3.521
Conformation-independent predicted aqueous solubility (CIQPlogS)	-3.83
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)	-2.962
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)	694.997
Predicted brain/blood partition coefficient (QPlogBB)	-0.309
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)	534.037
Predicted skin permeability, log Kp (QPlogKp)	-2.735
PM3 calculated ionization potential (IP(ev))	8.43
PM3 calculated electron affinity (EA(eV))	0.236
Number of likely metabolic reactions (#metab)	6
Prediction of binding to human serum albumin (QPlogKhsa)	-0.054
Predicted qualitative human oral absorption (HumanOralAbsorption)	3
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)	90.221
Solvent-accessible surface area of fluorine atoms (SAFluorine)	0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)	23.713
Van der Waals surface area (PSA)	78.725
Number of nitrogen and oxygen atoms (#NandO)	5
Number of violations of Lipinski’s rule of five (RuleOfFive)	0
Number of violations of Jorgensen’s rule of three (RuleOfThree)	0

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID	Gene name	Target name	TTD_ID	Prediction source
P23280	CA6	Carbonic anhydrase VI	T06569	SEA
P21918	DRD5	Dopamine D5 receptor	T46828	SEA
P18825	ADRA2C	Adrenergic receptor alpha-2	T01777	SEA
P52732	KIF11	Kinesin-like protein 1	T28484	SEA
O76074	PDE5A	Phosphodiesterase 5A	T07663	SEA
Q9HCR9	PDE11A	Phosphodiesterase 11A	T99802	SEA
P49862	KLK7	Kallikrein-7	T79155	SEA

Target associated diseases

TTD_ID	Disease_ID	Disease name	ICD_11	Uniprot ID	Gene names
T06569	DI0046	Bacterial infection	[ICD-11: 1A00-1C4Z]	P23280	CA6
T06569	DI0372	Seborrhoeic dermatitis	[ICD-11: EA81]	P23280	CA6
T46828	DI0022	Allergic/hypersensitivity disorder	[ICD-11: 4A80-4A8Z]	P21918	DRD5
T01777	DI0166	Glaucoma	[ICD-11: 9C61]	P18825	ADRA2C
T01777	DI0190	Hypertension	[ICD-11: BA00-BA04]	P18825	ADRA2C
T01777	DI0196	Hypotension	[ICD-11: BA20-BA21]	P18825	ADRA2C
T01777	DI0308	Obesity	[ICD-11: 5B80-5B81]	P18825	ADRA2C
T01777	DI0310	Ocular disease	[ICD-11: N.A.]	P18825	ADRA2C
T01777	DI0396	Substance abuse	[ICD-11: 6C40]	P18825	ADRA2C
T28484	DI0012	Acute myeloid leukaemia	[ICD-11: 2A60]	P52732	KIF11
T28484	DI0172	Head and neck cancer	[ICD-11: 2D42]	P52732	KIF11
T28484	DI0241	Lymphoma	[ICD-11: 2A80-2A86]	P52732	KIF11
T28484	DI0245	Malignant haematopoietic neoplasm	[ICD-11: 2B33]	P52732	KIF11
T28484	DI0274	Multiple myeloma	[ICD-11: 2A83]	P52732	KIF11
T28484	DI0321	Ovarian cancer	[ICD-11: 2C73]	P52732	KIF11
T28484	DI0361	Renal cell carcinoma	[ICD-11: 2C90]	P52732	KIF11
T28484	DI0391	Solid tumour/cancer	[ICD-11: 2A00-2F9Z]	P52732	KIF11
T07663	DI0190	Hypertension	[ICD-11: BA00-BA04]	O76074	PDE5A
T07663	DI0213	Innate/adaptive immunodeficiency	[ICD-11: 4A00]	O76074	PDE5A
T07663	DI0378	Sexual dysfunction	[ICD-11: HA00-HA01]	O76074	PDE5A
T07663	DI0411	Tonus and reflex abnormality	[ICD-11: MB47]	O76074	PDE5A